Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

CALVARUSO, Vincenza
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.448
EU - Europa 2.497
AS - Asia 921
AF - Africa 22
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
SA - Sud America 7
Totale 12.914
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.414
IT - Italia 985
CN - Cina 551
FI - Finlandia 301
UA - Ucraina 257
SG - Singapore 236
DE - Germania 202
IE - Irlanda 186
GB - Regno Unito 181
RU - Federazione Russa 117
SE - Svezia 82
FR - Francia 49
RO - Romania 48
KR - Corea 39
IN - India 30
BE - Belgio 29
CA - Canada 23
HK - Hong Kong 17
CI - Costa d'Avorio 14
CH - Svizzera 13
IR - Iran 12
MX - Messico 11
NL - Olanda 11
GR - Grecia 8
JP - Giappone 8
EU - Europa 7
TR - Turchia 7
AU - Australia 6
TW - Taiwan 6
BR - Brasile 5
EG - Egitto 5
AT - Austria 4
ES - Italia 4
PL - Polonia 4
NZ - Nuova Zelanda 3
UZ - Uzbekistan 3
VN - Vietnam 3
A2 - ???statistics.table.value.countryCode.A2??? 2
CZ - Repubblica Ceca 2
DK - Danimarca 2
EE - Estonia 2
IL - Israele 2
MD - Moldavia 2
PK - Pakistan 2
RS - Serbia 2
AF - Afghanistan, Repubblica islamica di 1
AR - Argentina 1
BG - Bulgaria 1
BY - Bielorussia 1
CM - Camerun 1
EC - Ecuador 1
GH - Ghana 1
HR - Croazia 1
ID - Indonesia 1
MY - Malesia 1
NO - Norvegia 1
PT - Portogallo 1
SA - Arabia Saudita 1
SI - Slovenia 1
TG - Togo 1
TH - Thailandia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 12.914
Salva come PNG Salva come JPEG
Città #
Fairfield 1.687
Ashburn 1.009
Woodbridge 806
Houston 682
Seattle 660
Chandler 635
Wilmington 633
Cambridge 583
Ann Arbor 381
Medford 227
Palermo 208
Singapore 192
Altamura 191
Dublin 186
Des Moines 143
Princeton 142
Lawrence 133
Nanjing 132
Jacksonville 120
San Diego 101
New York 71
Dearborn 68
Boardman 61
Beijing 57
Tulsa 53
Ludwigshafen am Rhein 48
Shenyang 48
London 44
Santa Clara 44
Hebei 38
Nanchang 35
Milan 32
Jinan 31
Changsha 30
Brussels 29
San Paolo di Civitate 29
Tianjin 28
Jiaxing 27
Phoenix 25
Saint Petersburg 25
Redwood City 24
Ningbo 22
Falls Church 20
Seongnam 20
Rome 19
Los Angeles 17
Zhengzhou 15
Abidjan 14
Dallas 14
Helsinki 14
Ottawa 14
Venice 14
Hangzhou 12
Orange 12
Hounslow 11
Kumar 11
Bremen 10
Foggia 10
Guangzhou 10
Lappeenranta 10
Munich 10
Taizhou 10
Auburn Hills 9
Seoul 9
Tehran 9
Central 8
Chicago 8
Florence 8
Cuauhtémoc 7
Catania 6
Hong Kong 6
Kilburn 6
Kunming 6
Messina 6
Napoli 6
Norwalk 6
Piacenza 6
Pune 6
Taipei 6
Verona 6
Aachen 5
Augusta 5
Cagliari 5
Chiswick 5
Hefei 5
Moscow 5
Nürnberg 5
Salerno 5
San Mateo 5
Taiyuan 5
Tappahannock 5
Vicopisano 5
Bari 4
Castelbuono 4
Columbus 4
Den Haag 4
Edinburgh 4
Fuzhou 4
Haikou 4
Indiana 4
Totale 10.203
Salva come PNG Salva come JPEG
Nome #
Hepatitis C Virus Eradication by Direct Antiviral Agents Improves Carotid Atherosclerosis in patients with Severe Liver Fibrosis 193
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis 169
HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals 167
Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. 152
Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: The International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program 151
Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis 150
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program. 149
Clinical course and outcomes of drug-induced liver injury: Nimesulide as the first implicated medication. 147
Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension:a randomized controlled trial 143
IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection. 141
Clinical implications of the hyperdynamic syndrome in cirrhosis. 139
A simple, noninvasive test for the diagnosis of liver fibrosis in patients with hepatitis C recurrence after liver transplantation. 138
Role of IL-28B and inosine triphosphatase polymorphisms in efficacy and safety of Peg-Interferon and ribavirin in chronic hepatitis C compensated cirrhosis with and without oesophageal varices. 138
Fibrosis Evaluation by Transient Elastography in Patients With Long-Term Sustained HCV Clearance 138
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents 138
Disease outcomes after DAA-induced SVR: Data from the resist-HCV cohort 135
Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension 134
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease 134
An evaluation of transient elastography in the discrimination of HBeAg-negative disease from inactive hepatitis B carriers 130
Different doses of consensus interferon plus ribavirin in patients with hepatitis C virus genotype 1 relapsed after interferon monotherapy: a randomized controlled trial 129
Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects 129
Improved survival of patients with hepatocellular carcinoma and compensated hepatitis C virus-related cirrhosis who attained sustained virological response 129
Comparison of Histochemical Staining Methods and Correlation with Transient Elastography in Acute Hepatitis. 128
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis 128
Suboptimal performance of APRI and FIB-4 in ruling out significant fibrosis and confirming cirrhosis in HIV/HCV co-infected and HCV mono-infected patients 128
Direct acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 127
Hepatocellular carcinoma and direct-acting antivirals: A never ending story? 127
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D. 126
Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition. 125
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study 124
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C 122
AISF position paper on liver disease and pregnancy. 122
Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis 121
Comparison of cystatin C and creatinine-based glomerular filtration rate formulas with 51Cr-EDTA clearance in patients with cirrhosis 120
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 120
The course of oesophagogastric varices in patients with cirrhosis after DAA-induced HCV clearance 119
Liver collagen proportionate area predicts decompensation in patients with recurrent hepatitis C virus cirrhosis after liver transplantation 118
The impact of sustained virological response on clinical outcomes in compensated HCV cirrhosis: a prospective cohort study 117
Fibrosis staging in chronic hepatitis C: analysis of discordance between transient elastography and liver biopsy 117
Impact of virus eradication in patients with compensated hepatitis C virus-related cirrhosis: competing risks and multistate model 117
Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience 117
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 115
Implication of Normal Liver Enzymes in Liver Disease 114
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis 114
Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation 113
Identification of naïve HCV-1 patients with chronic hepatitis who may benefit from dual therapy with peg-interferon and ribavirin 111
Point-of-care HCV RNA testing in the setting of DAA therapy: HCV-FiS (HEpatitis C Virus Fingerstick Study) 110
Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients 110
Coagulation and fibrosis in chronic liver disease. 109
Histological subclassification of cirrhosis 108
Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study 108
Impact of Tips Preliver Transplantation for the Outcome Posttransplantation 107
NT pro BNP plasma level and atrial volume are linked to the severity of liver cirrhosis. 106
Non-invasive prediction of esophageal varices by stiffness and platelet in non-alcoholic fatty liver disease cirrhosis 106
Regression of fibrosis after HBV antiviral therapy. Is cirrhosis reversible? 106
Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis 104
Computer-Assisted Image Analysis of Liver Collagen: Relationship to Ishak Scoring and Hepatic Venous Pressure Gradient 102
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial. 102
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 101
Survival of patients with HCV cirrhosis and sustained virologic response is similar to the general population. 101
Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens? 101
Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-alcoholic fatty liver disease patients 101
Who is more likely to respond to dual treatment with pegylated-interferon and ribavirin for chronic hepatitis C? A gender-oriented analysis. 100
RIFLE classification as predictive factor of mortality in patients with cirrhosis admitted to intensive care unit. 99
Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies 99
Models for non-alcoholic fatty liver disease: a link with vascular risk. 98
Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. 98
Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel 98
Baveno VII – Renewing consensus in portal hypertension 98
TACE versus TAE as therapy for hepatocellular carcinoma. 97
Critically ill patients with cirrhosis and low serum sodium. 97
Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis 95
HCV CLEARANCE AFTER PEG IFN PLUS RBV IMPROVES THE COURSE OF HCV CIRRHOSIS REGARDLESS OF PORTAL HYPERTENSION 93
Predictors of Re‐bleeding and Mortality Among Patients with Refractory Variceal Bleeding Undergoing Salvage Transjugular Intrahepatic Portosystemic Shunt (TIPS) 93
Real life experiences in HCV management in 2018 93
High efficacy of direct-acting anti-viral agents in hepatitis C virus-infected cirrhotic patients with successfully treated hepatocellular carcinoma. 93
CLINICAL COURSE OF NIMESULIDE-INDUCED LIVER INJURY 92
Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens 92
AISF position paper on liver transplantation and pregnancy: Women in Hepatology Group, Italian Association for the Study of the Liver (AISF). 92
Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? the REAL Experience 92
LIVER RELATED EVENTS AND SURVIVAL IN PATIENTS WITH COMPENSATED HCV CIRRHOSIS: THE ROLE OF SUSTAINED VIROLOGICAL RESPONSE TO PEG-IFN BASED THERAPY AND PORTAL HYPERTENSION 91
Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication? 91
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy 90
Fibrosis in chronic viral hepatitis 90
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. 89
Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. 88
HBV recurrence after HCV clearance on DAAs: Sometimes they come back 88
Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication 88
Residual risk of hepatocellular carcinoma after HCV eradication: more than meets the eye. 87
Is global elimination of HCV realistic? 86
Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated hepatitis C virus cirrhosis 85
Hepassocin as a treatment for fulminant hepatic failure: will it translate from rats to human? 85
Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis. 85
Immunological alterations in hepatitis C virus infection 82
The impact of sustained virological response on clinical outcome in compensated HCV cirrhosis: a prospective cohort study 81
Prospective comparison of Fibroscan, King's score and liver biopsy for the assessment of cirrhosis in chronic hepatitis C infection. 80
Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy 77
Meccanismi immunologici e molecolari del danno epatico da farmaci 76
Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network 75
The risk of hepatocellular carcinoma in HBV cirrhosis is affected by polymorphisms of the MERTK gene 75
Totale 11.153
Salva come PNG Salva come JPEG
Categoria #
all - tutte 57.953
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 57.953
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20203.379 0 0 263 550 410 504 402 299 417 187 221 126
2020/20211.797 126 150 156 146 114 75 95 147 197 240 159 192
2021/20221.752 58 318 149 53 46 67 132 115 213 163 148 290
2022/20232.133 212 488 39 186 247 298 119 148 246 16 73 61
2023/2024922 39 106 82 55 80 226 102 48 18 24 28 114
2024/2025402 95 244 63 0 0 0 0 0 0 0 0 0
Totale 13.582